CD5+diffuse large B-cell lymphoma(CD5+DLBCL) is known to have different characteristics than CD5−DLBCL and mantle cell lymphoma(MCL). 9 patients with CD5+DLBCL were reviewed, and the results were compared with those of 8 CD5−DLBCL and 3 cyclin D1+MCL patients. CD5+DLBCL was more closely related to many aggressive clinical features or parameters than CD5−DLBCL : 67% of the patients were older than 60 years, 67% with performance status ≧2, 89% with serum lactate dehydrogenase level higher than normal, 78% with stage III/IV disease at diagnosis, and 78% with more than one extranodal lesion. The overall International Prognostic Index score for the patients with CD5+DLBCL was thus sig-nificantly higher than that for those with CD5−DLBCL.
Immunophenotypically, CD5+DLBCL was characterized by CD5+CD10−CD19+CD20+CD21−CD23−cyclin D1−phenotype and the predominant expression of surface IgM. Of particular interest is that the survival rate of CD5+DLBCL patients was significantly inferior to that of patients with CD5−DLBCL. To further characterize CD5+DLBCL, we semi-quantified the CD5 expression in DLBCL cells. Our findings suggest that CD5+DLBCL may constitute a unique subgroup of DLBCL and, moreover, CD5+DLBCL may consist of several subgroups.
[Rinsho Byori 50 : 906〜911, 2002]
*1Department of medical technology Kagawa Prefectural College of health sciences, Kida-gun, kagawa-pref. 761-0123
受付2002年5月31日・受理2002年8月13日
*1香川県立医療短期大学臨床検査学科(〒761-0123 香川県木田郡牟礼町大字原281番地1)
*2,4〜6香川医科大学医学部附属病院検査部,*3,14同 臨床検査医学,*7同 輸血部,*8同 環境保健科学,
*9〜13同 第一内科(〒761-0793 香川県木田郡三木町池戸1750-1)
E-mail :manabe@chs.pref.kagawa.jp